FLT1 and renal cell carcinoma: Similarly, tivozanib is an inhibitor of VEGFR1, VEGFR2, VEGFR3, and PDGFRβ, approved by the U.S. FDA in 2021 for the third-line therapy for advanced RCC (132–134).